Regulation of Fuzheng Huayu capsule on inhibiting the fibrosis-associated hepatocellular carcinogenesis.

LIVER tumors; CHINESE medicine; RISK assessment; CIRRHOSIS of the liver; ARACHIDONIC acid; HERBAL medicine; HYDROCARBONS; IN vivo studies; QUALITY control; CELLULAR signal transduction; DESCRIPTIVE statistics; BIOINFORMATICS; QUERCETIN; GENES; EXPERIMENTAL design; IMMUNOHISTOCHEMISTRY; ANIMAL experimentation; MOLECULAR structure; ONE-way analysis of variance; CARCINOGENESIS; LIVER; COMPARATIVE studies; DATA analysis software; HEPATOCELLULAR carcinoma; PHARMACEUTICAL encapsulation; NITROSOAMINES; TUMOR necrosis factors; ALGORITHMS; DISEASE progression; SEQUENCE analysis; LIVER function tests; NONPARAMETRIC statistics

In the current study, bioinformatics analysis of the hepatocellular carcinoma (HCC) dataset was conducted with the hepatoprotective effect of the Fuzheng Huayu (FZHY) capsule against the diethylnitrosamine-induced HCC progression analyzed. Eight cell clusters were defined and tanshinone IIA, arachidonic acid, and quercetin, compounds of the FZHY capsule, inhibit HCC progression-related fibrosis by regulating the expression of PLAU and IGFBP3. Combined with the ameliorative effect of the FZHY capsule against liver dysfunctions and expression of PLAU and IGFBP3, our study confirmed the effect of the FZHY capsule on inhibiting the fibrosis-associated HCC progression via regulating the expression of PLAU and IGFBP3. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Asian Natural Products Research is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)